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ABSTRACT
Technologies may have implications for improving clinical diagnosis and 
prognosis, and for the development of therapeutic interventions, specific 
biomarkers, and preventive strategies. Given the amount of existing and ever-
growing quantitative assessments using technology in PD, clinicians, patients 
and researchers are faced with the challenge of deciding which assessment 
tool to use in the laboratory, clinic and home environment. In order to 
facilitate this decision-making a systematic review was done to identify and 
classify the available monitoring technologies for individuals with PD over the 
last 2 decades. This is a commentary on the systematic review which adds on 
discussion on some controversial issues in the area.  It tackles some of current 
open-to-discussion topics in the technology field, such as: which definitions 
to use, the heterogeneity of the clinimetric properties among technologies, 
standardization of a validation process, how to group different measuring 
technologies, and the need to conduct further studies on existing technologies 
before developing new ones. The strength of this comprehensive, timely and 
useful review is the detailed and robust approach taken by authors to classify 
technologies as listed, suggested, or recommended for the assessment of 
individuals with PD. 
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Commentary
The main challenges faced by the technology field include synthesizing the vast type of technologies being developed for use in Parkinson´s disease (PD), organizing the amount of raw data obtained and how to meet the needs of both clinicians and patients, and providing trends and highlights of a patient’s status. The authors of this paper sought to provide answers to such challenges by performing a systematic review of the available monitoring technologies for individuals with PD over the last 2 decades. Given the complexity of the controversy issues in technology, the authors further discuss the challenging topics raised in the form of this commentary. These technologies may have implications for improving clinical diagnosis and prognosis, and for 
the development of therapeutic interventions, specific biomarkers, and preventive strategies. Given the amount of existing and ever-growing quantitative assessments using technology in PD, this paper will hopefully facilitate decision-making by clinicians, patients and researchers when deciding which assessment tool to use in the laboratory, clinic and home environment. The authors classify technologies as listed, suggested, or recommended for the assessment of individuals with 
PD. These classifications are based on 3 criteria, namely: 1) used in the assessment of PD; 2) used by individuals other 
than the developers; and 3) have undergone successful clinimetric testing. The authors conclude with a summary of the recommended technologies that can objectively assess several PD signs (postural control, tremor, bradykinesia, freezing, dyskinesia, gait, and daily activity/physical activity) and comment on which other disease-related aspects need more attention such as disease progression markers and non-motor symptoms (cognition, sleep and dysphagia).
Controversial Issues: Clinimetric Data Validation One of the controversial issues that are highlighted in this paper concerns the clinimetric data validation process of the technologies reviewed. The validity criteria of a system are an interesting but also complex concept. The authors argue that technologies have not undergone a formal validation process and should be assessed based on validity criteria similar to, or adapted from those used 
for clinical scales (for examples: Goetz, Tilley et al. 2008 
1; Colosimo, Martinez-Martin et al. 2010 2; Elble, Bain 
et al. 2013 3). Given the current gap in knowledge on the proper clinimetric properties of devices applied as evaluation tools, the technology devices and systems are therefore evaluated against clinical application criteria. Recommendations were limited to the available data 
and specific to the motor disorder or sometimes specific metrics that where validated for that device. 
Importantly, there are many types and degrees of validity. Combining all types of validity into a single yes/
no binary answer may not accurately reflect the validity of a certain system. Unfortunately, limited data were available from primary sources, validation processes were dispersed, and while some focused on validating the algorithm, others focused on the metrics or on the device itself. On a positive note, the authors highlight that they only considered whether any kind of validity had been performed, and given the complexity of information in this area any validation was accepted in the yes/no binary.Additionally, when analyzing any technology system, readers should be aware of what the “nature of the comparison-validation” was when assessing the system. For example, when comparing an accelerometer-based system to an instrumented mattress or to a three-dimensional motion capture system, it is important to ensure that systems measuring different signals were compared (acceleration vs. pressure vs. position). This has been highlighted in this review and was believed not to 
impact classification of the technology instruments, as the aim of the review was to report only the existing published validation data. However, another possible method to validate technology could be the COSMIN framework of measurement properties which provides taxonomy and 
definitions of which measurement properties are important for outcome measures4. Within this framework, a checklist was also developed containing standards for assessing the methodological quality of studies on measurement properties for patient-reported outcome measures5 and can ultimately be adapted and used in a systematic review of technologies. Importantly, in order to truly establish a fair comparison 
across different technologies used in PD and reflect the state-of-the-art of that technology, we will need  an  in-depth  review  of  important  aspects  of  existing  technology devices,  such as sensor  types  and  positions,  data collection  protocols,  subject  groups,  feature  extractors, 
classification  methods  and  performance  measures.  
Controversial issues: Difficulties in sStandard 
Terminology and Grouping Technologies
One of the bottlenecks identified in the review refers 
to the use of terminology in the field of technologies and 
how the different technologies are grouped or classified. 
Reflecting on how technologies, technological instruments, 
or technology-based devices are defined currently and how this has changed over the years, might be of interest. This lack of standardization could represent a serious methodological pitfall for the evaluation and interpretation of assessment and intervention strategies using such technologies. This may not be as intuitive as it seems. For example, could a system that is based on a sensor attached 
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on the body, yet requiring constant communication with 
a short range fixed-base station be considered wearable? 
Coming up with a definition for a wearable system might not be straight forward but it is notable that some effort was made to better clarify the use of terminologies and 
definitions. As such, an effort was made to positively 
contribute to this standardization of definitions. Wearable 
devices were defined as electronic technology or computers designed to be worn on the body, or embedded into watches, bracelets, clothing, and others. Less known terms 
such as hybrid were also carefully defined as the blend of technologies that combined wearable and non-wearable devices.Grouping these technologies is also a challenge. Some 
previous studies have focused on specific motor and non-
motor deficits in PD and review which wearables were used to assess them (problem-based structure)6. Other 
option for classifications may focus on specific construct and review which technology/ instrument can be used 
for measuring a specific construct (construct-based structure). Yet, the challenge of classifying technologies may be because technologies can measure multiple disease 
related deficits or constructs at the same time and this may ultimately complicate the assessment of reliability and validity.In this review, a device-based structure was used focusing on which devices exist and for what use. This could ultimately transmit the image of a simple inventory of the available systems and limit the clinical applicability because PD symptoms are not intuitively highlighted or it is not totally clear which device covers which motor disorder and at what level. A device might have only been assessed for example for sway but not for tremor. The 
supplementary table or the main manuscript would benefit from an additional problem-based approach where a reader who is interested only in freezing of gait can identify the devices that are better recommended for this purpose. Such a problem-based structured divided between motor, non-motor problems and disease-related complications may ultimately better guide clinicians in their decisions. Importantly, care needs to be taken to avoid endless repetition of data because many devices can be used for multiple purposes (e.g., sway, gait, or tremor) but may meet criteria for only a certain subset.
Recommendations for Future Studies and need for 
CollaborationOverall, this paper provides an overview of the application of clinical methodological criteria applied in other reviews of scales and assessment tools in PD, and currently available technology devices. Regardless of the limitations of the available data, some useful and clinically relevant recommendations regarding which devices should 
be prioritized in the clinic and in research could be made using these criteria. This could help set the grounds for 
thinking about developing/defining a core outcome set of measurement instruments to be used in research in PD7.Technology development is currently based on competitive and individual initiatives allowing for duplication of efforts instead of collaborative work to develop complementary technologies. Additionally, technologies may be driven by ease of development as opposed to clinical need for a technical solution. Such developments will also soon face the need for establishing business models to cover the costs and regulatory 
validation of their efficacy and safety. Any new development should keep in mind some key requirements such as reliability, low cost, small size, low power consumption, and clinical relevance. Technology applications relying on mobile phones may have additional value because smart phones are broadly available and make system use and maintenance quick and cost-effective. Yet, one must keep in mind that each new brand of a phone that is developed can be considered a “new technology device”, given it has different gyro/acceleration, barometer or GPS location systems, and thus can potentially give different metrics. As such, larger sample studies using phones will need to consider a starting calibration setup, allowing for a cross validation model. Additionally, the placement of the phone is another aspect that needs to be considered. There is evidence suggesting the waist as the optimal placement given its proximity to the centre of mass8. Yet the common place people use phones would be in the bags of pockets. An additional thought of a band of the wrist (smartwatch) can be ultimately an alternative solutions, given its cost effectiveness, usability in both indoor  and  outdoor environments,  and  ability  to  track  a  patient  using  the GPS  module  in  the  phone that can ultimately be useful for fall events by allow  timely  assistance  and intervention. So, alongside using technology for making assessments, it is worth focusing on how to move forward to developing devices for safety monitoring, such as detecting falls with advanced signal processing techniques to achieve high accuracy of falls detection with alarm messages to an emergency response system. Another clinical situation where technology applications may deserve particular interest is monitoring PD patients with cognitive impairment and building systems that could assist these patients with remembering daily activities, tracking medication compliance and monitoring daily behavior for early signs of deterioration, allowing such patients to live independently for longer. 
Despite the tremendous progress in this field and the development of numerous new technologies, we emphasize the need for further studies on the existing recommended technologies as opposed to developing new technology 
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devices.However, some technological systems have been used for many years in different settings, diseases and teams from different geographies. So different needs such as wanting to clinically validate a new biometric outcome to be used on a collaborative study on monitoring a particular clinical issue of PD might justify the merge old with new technologies, the development of new proximate devices, and standardized methods of clinical evaluation and data extraction. As such, present and future technologies will 
probably always have a very important scientific role.We thus await, with interest, future results for these and/or new recommended technologies used in clinical studies as standardized measures of disease progression, allowing for comparison between trials and representing 
more accurate measures of clinically efficacy.
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